Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women. Inter99 (2)

Elevation in plasma total homocysteine (tHcy) is believed to be causally related to cardiovascular disease. Like age and sex, the thermolabile variant of methylenetetrahydrofolate reductase (MTHFR(C677T)) is an important nonmodifiable determinant of tHcy, which may be considered when describing normal ranges of tHcy in the general population. We investigated the simultaneous effect of sex, age, and MTHFR(C677T) genotype on the distribution of tHcy in a cross‐sectional study design. THcy concentrations and MTHFR(C677T) genotype were determined in a population‐based sample of 2,788 Danish men and women aged 30–60 years participating in the Inter99 Study. The prevalences of MTHFR(C677T) genotypes were 48.8% (CC), 42.4% (CT), and 8.8% (TT). The overall median tHcy was 8.1 µmol/l, and the 2.5–97.5 percentiles were 4.8–17.8 µmol/l. The estimated proportionally higher level of tHcy in men compared to women was 14.3% (P<0.001). A significant interaction term was found between age and MTHFR(C677T) genotype (P<0.001). The estimated changes in tHcy per 5 years of age were 1.5% in CC individuals (P<0.01), 2.1% in CT individuals (P<0.001), and −4.1% in TT individuals (P<0.01). The T allele was associated with elevated tHcy. However, the proportionally higher level of tHcy in TT individuals compared to CT and CC individuals decreased with increasing age. The MTHFR(C677T) polymorphism explained 6% of the phenotypic variation in tHcy. In conclusion, we found that tHcy is associated with sex, age, and MTHFR genotype. Our results indicate that the effect of age is modified by MTHFR genotype. Genet Epidemiol 24:322–330, 2003. © 2003 Wiley‐Liss, Inc.

[1]  B. Abrahamsen,et al.  Association of a Common Allelic Polymorphism (C677T) in the Methylene Tetrahydrofolate Reductase Gene with a Reduced Risk of Osteoporotic Fractures. A Case Control Study in Danish Postmenopausal Women , 2002, Calcified Tissue International.

[2]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[3]  G. Russo,et al.  The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. , 2002, The Journal of nutrition.

[4]  P. Mueller,et al.  Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. , 2002, International journal of epidemiology.

[5]  K Borch-Johnsen,et al.  A New Method for Chd Prediction and Prevention Based on Regional Risk Scores and Randomized Clinical Trials; PRECARD® and the Copenhagen Risk Score , 2001, Journal of cardiovascular risk.

[6]  S. Vollset,et al.  Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. , 2001, The American journal of clinical nutrition.

[7]  H. Boeing,et al.  Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam study. , 2001, Metabolism: clinical and experimental.

[8]  H. Blom,et al.  The homocysteine distribution: (mis)judging the burden. , 2001, Journal of clinical epidemiology.

[9]  S. Vollset,et al.  Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. , 2000, Clinical chemistry.

[10]  A. Hofman,et al.  Increased plasma homocysteine after menopause. , 2000, Atherosclerosis.

[11]  S. Vollset,et al.  Total homocysteine and cardiovascular disease , 1999, Journal of internal medicine.

[12]  W. Ewens.  Genetics and analysis of quantitative traits , 1999 .

[13]  L. Kluijtmans,et al.  Reduced frequency of the thermolabile methylenetetrahydrofolate reductase genotype in the elderly. , 1999, Atherosclerosis.

[14]  I. Rosenberg,et al.  Serum Total Homocysteine Concentrations in the Third National Health and Nutrition Examination Survey (19911994): Population Reference Ranges and Contribution of Vitamin Status to High Serum Concentrations , 1999, Annals of Internal Medicine.

[15]  C. Laskin,et al.  Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. , 1999, Placenta.

[16]  M. Gaustadnes,et al.  Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  I. Rosenberg,et al.  Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. , 1999, The American journal of clinical nutrition.

[18]  M. Creer,et al.  Interlaboratory variability for total homocysteine analysis in plasma. , 1999, Clinical chemistry.

[19]  D. Wilcken,et al.  Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. , 1998, Circulation.

[20]  P. Ueland,et al.  A common methylenetetrahydrofolate reductase gene mutation and longevity. , 1998, Atherosclerosis.

[21]  Niels Keiding,et al.  A comparison of mortality rates in three prospective studies from Copenhagen with mortality rates in the central part of the city, and the entire country , 1998, European Journal of Epidemiology.

[22]  A. Kessling,et al.  MTHFR association with arteriosclerotic vascular disease? , 1998, Human Genetics.

[23]  H. Blom,et al.  Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials , 1998, BMJ.

[24]  S. Vollset,et al.  Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. , 1998, The American journal of clinical nutrition.

[25]  A. Grubb,et al.  The Increase of Plasma Homocysteine Concentrations with Age Is Partly due to the Deterioration of Renal Function as Determined by Plasma Cystatin C , 1998, Clinical chemistry and laboratory medicine.

[26]  K. Rasmussen,et al.  An external quality assessment study on the analysis of methylmalonic acid and total homocysteine in plasma. , 1997, Scandinavian journal of clinical and laboratory investigation.

[27]  P. Ueland,et al.  Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. , 1997, Kidney international.

[28]  P. Ueland,et al.  Assessment of homocysteine status , 1997, Journal of Inherited Metabolic Disease.

[29]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. , 1997, Cancer research.

[30]  M. Stanton,et al.  Homocysteine and cardiovascular disease , 2011 .

[31]  S. Vollset,et al.  Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. , 1995, JAMA.

[32]  H. Blom,et al.  Plasma homocysteine and menopausal status ** , 1995, European journal of clinical investigation.

[33]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[34]  A. Lindgren,et al.  Homocysteine and cysteine: determinants of plasma levels in middle‐aged and elderly subjects , 1994, Journal of internal medicine.

[35]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[36]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[37]  S. S. Kang,et al.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. , 1988, American journal of human genetics.

[38]  A. Bree.  Dietary, lifestyle and genetic determinants of homocysteine, and its relation with coronary heart disease , 2001 .

[39]  V. Gudnason,et al.  Gene-environment and Gene-gene Interaction in the Determination of Plasma Homocysteine Levels in Healthy Middle-aged Men , 2001, Thrombosis and Haemostasis.

[40]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[41]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[42]  H. Blom,et al.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. , 1995, American journal of human genetics.